Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amy Nguyen

Optometrist Orange, CA Doctor of Optometry

NPI 1538651948 CMS profile 5450777

293 S Main St Ste 100, Orange, CA 92868

Open in the dashboard

General payments

$14,900

464 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Nguyen of Orange, CA is reported in the CMS Open Payments database as having received $14,900 across 464 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $314 7
2024 General $121 1
2023 General $305 4
2022 General $2,903 79
2021 General $5,831 156
2020 General $2,397 89
2019 General $3,029 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Nguyen
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Amy Nguyen were reported at $314. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Amy Nguyen Optometrist median Middle half National median
2019 $3,029 $159 $67–$371 $163
2020 $2,397 $72 $29–$165 $114
2021 $5,831 $125 $46–$292 $132
2022 $2,903 $162 $66–$374 $149
2023 $305 $177 $72–$406 $160
2024 $121 $188 $77–$427 $164
2025 $314 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aerie Pharmaceuticals, Inc. $2,161 102 payments
  2. RxSight Inc $1,621 2 payments
  3. Sight Sciences, Inc. $1,295 39 payments
  4. Bausch & Lomb, a division of Bausch Health US, LLC $1,289 74 payments
  5. Alcon Vision LLC $1,249 42 payments
  6. Oyster Point Pharma, Inc. $824 10 payments
  7. Dompe US, Inc. $749 17 payments
  8. Glaukos Corporation $725 4 payments
  9. Sun Pharmaceutical Industries Inc. $675 22 payments
  10. Kala Pharmaceuticals, Inc. $589 25 payments
  11. Other $3,722 127 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,749 458 payments
  2. Consulting Fee $2,000 2 payments
  3. Gift $121 1 payment
  4. Education $30 3 payments
Products named General payments · program years 2019–2025
  1. rhopressa Glaucoma $1,660 70 payments
  2. rocklatan $1,647 69 payments
  3. LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD) $1,621 2 payments
  4. OMNI(R) SURGICAL SYSTEM (US) $969 33 payments
  5. VYZULTA $909 55 payments
  6. TYRVAYA $824 10 payments
  7. OXERVATE $749 17 payments
  8. EYSUVIS $589 25 payments
  9. Rhopressa Glaucoma $502 32 payments
  10. Cequa $467 11 payments
  11. Other $8,007 319 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

464 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record